as 06-06-2025 4:00pm EST
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
Founded: | 2005 | Country: | United States |
Employees: | N/A | City: | WATERTOWN |
Market Cap: | 5.8M | IPO Year: | 2020 |
Target Price: | $100.00 | AVG Volume (30 days): | 1.9M |
Analyst Decision: | Buy | Number of Analysts: | 2 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -60.66 | EPS Growth: | N/A |
52 Week Low/High: | $3.81 - $37.50 | Next Earning Date: | 05-06-2025 |
Revenue: | $1,185,000 | Revenue Growth: | -29.46% |
Revenue Growth (this year): | -23.66% | Revenue Growth (next year): | 1286.17% |
LYRA Breaking Stock News: Dive into LYRA Ticker-Specific Updates for Smart Investing
Zacks
2 days ago
MT Newswires
5 days ago
GuruFocus.com
5 days ago
MT Newswires
5 days ago
GlobeNewswire
5 days ago
GlobeNewswire
a month ago
Zacks
a month ago
GlobeNewswire
a month ago
The information presented on this page, "LYRA Lyra Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.